Anticancer agent 267

• Description :

  Anticancer agent 267 (Compound 5q) is the activator for RIPK3 and MLKL. Anticancer agent 267 inhibits the proliferation in a variety of cancer cell lines (IC50 for MDA-MB-231, MDA-MB-486 and MCF-7 is 9.79, 10.77 and 5.94 μM, respectively), arrests cell cycle at subG1 phase, and induces necroptosis in cell MDA-MB-231. Anticancer agent 267 exhibits antitumor activity in mouse xenograft models[1].

• UNSPSC :

  12352005

• Target :

  Mixed Lineage Kinase; Necroptosis; RIP kinase

• Related Pathways :

  Apoptosis; MAPK/ERK Pathway

• Field of Research :

  Cancer

• Smiles :

  O=C(C(N/N=C/C1=CC=C([N+]([O-])=O)S1)=O)NCC2=CC=CC=N2

• Molecular Formula :

  C13H11N5O4S

• Molecular Weight :

  333.32

• References & Citations :

  [1]Akhavan R, et al., Discovery of a new hydrazone-oxamide hybrid capable of inducing necroptotic cell death in triple negative breast cancer cells. Bioorg Chem. 2025 Apr;157:108267.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported